Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,933 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteasome inhibitors for multiple myeloma.
Okazuka K, Ishida T. Okazuka K, et al. Among authors: ishida t. Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793. doi: 10.1093/jjco/hyy108. Jpn J Clin Oncol. 2018. PMID: 30102324 Review.
[Chemotherapy for multiple myeloma].
Ishida T. Ishida T. Nihon Rinsho. 2007 Dec;65(12):2280-4. Nihon Rinsho. 2007. PMID: 18069273 Review. Japanese.
Model of translational cancer research in multiple myeloma.
Yasui H, Ishida T, Maruyama R, Nojima M, Ikeda H, Suzuki H, Hayashi T, Shinomura Y, Imai K. Yasui H, et al. Among authors: ishida t. Cancer Sci. 2012 Nov;103(11):1907-12. doi: 10.1111/j.1349-7006.2012.02384.x. Epub 2012 Aug 17. Cancer Sci. 2012. PMID: 22809142 Free PMC article. Review.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. Watanabe T, et al. Among authors: ishida t. Br J Haematol. 2016 Mar;172(5):745-56. doi: 10.1111/bjh.13900. Epub 2016 Jan 5. Br J Haematol. 2016. PMID: 26732066 Free PMC article. Clinical Trial.
[IgE-κ type multiple myeloma achieving complete response with novel agents].
Takei T, Ishida T, Ikeda M, Shingaki S, Miyazaki K, Yoshiki Y, Abe Y, Okazuka K, Iki S, Tsukada N, Suzuki K. Takei T, et al. Among authors: ishida t. Rinsho Ketsueki. 2017;58(11):2232-2237. doi: 10.11406/rinketsu.58.2232. Rinsho Ketsueki. 2017. PMID: 29212974 Review. Japanese.
4,933 results